Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 2 2000
Play
Audio Below:
We
now have several more trials that show that in receptor-positive
patients – and these more recent trials were restricted to
receptor-positive patients in contrast to all trials that went before
– ovarian ablation certainly was as good as IV CMF, and in
fact, there’s almost a suggestion it was better. So I think
that’s the second thing – that of course, the trial from
the ECOG where randomized to what everybody would consider state-of-the-art
chemotherapy CAF, you get some additional benefit from adding ovarian
ablation. And, certainly among the women under age 40, there was
no question about what you did. And my reading of that study –
and it did change my thinking, maybe more so even than the primary
authors – is that this is the most powerful evidence we have
yet that a major component of adjuvant chemotherapy is ovarian ablation.
And I now have moved to the point, which some people would say its
an over interpretation – but it’s where I am, that if
a woman has adjuvant chemotherapy and she does not stop menstruating,
then I routinely add a LHRH agonist at this point.
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
